EP1551221A4 - Compositions d'acide nucleique destinees a stimuler les reponses immunitaires - Google Patents

Compositions d'acide nucleique destinees a stimuler les reponses immunitaires

Info

Publication number
EP1551221A4
EP1551221A4 EP03763239A EP03763239A EP1551221A4 EP 1551221 A4 EP1551221 A4 EP 1551221A4 EP 03763239 A EP03763239 A EP 03763239A EP 03763239 A EP03763239 A EP 03763239A EP 1551221 A4 EP1551221 A4 EP 1551221A4
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
immune responses
acid compositions
stimulating immune
stimulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03763239A
Other languages
German (de)
English (en)
Other versions
EP1551221A2 (fr
Inventor
Arthur M Krieg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Coley Pharmaceutical Group Inc
Original Assignee
Coley Pharmaceutical Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coley Pharmaceutical Group Inc filed Critical Coley Pharmaceutical Group Inc
Publication of EP1551221A2 publication Critical patent/EP1551221A2/fr
Publication of EP1551221A4 publication Critical patent/EP1551221A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
EP03763239A 2002-07-03 2003-07-03 Compositions d'acide nucleique destinees a stimuler les reponses immunitaires Withdrawn EP1551221A4 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US39409002P 2002-07-03 2002-07-03
US39409102P 2002-07-03 2002-07-03
US39416402P 2002-07-03 2002-07-03
US39388002P 2002-07-03 2002-07-03
US39419302P 2002-07-03 2002-07-03
US394193P 2002-07-03
US394090P 2002-07-03
US393880P 2002-07-03
US394164P 2002-07-03
US394091P 2002-07-03
PCT/US2003/021113 WO2004005476A2 (fr) 2002-07-03 2003-07-03 Compositions d'acide nucleique destinees a stimuler les reponses immunitaires

Publications (2)

Publication Number Publication Date
EP1551221A2 EP1551221A2 (fr) 2005-07-13
EP1551221A4 true EP1551221A4 (fr) 2007-08-01

Family

ID=30119452

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03763239A Withdrawn EP1551221A4 (fr) 2002-07-03 2003-07-03 Compositions d'acide nucleique destinees a stimuler les reponses immunitaires

Country Status (7)

Country Link
EP (1) EP1551221A4 (fr)
JP (2) JP2005532067A (fr)
CN (1) CN1678188B (fr)
AU (1) AU2003247880B2 (fr)
CA (1) CA2494508A1 (fr)
SG (1) SG167667A1 (fr)
WO (1) WO2004005476A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1572122A4 (fr) 2002-11-01 2008-04-09 Us Gov Health & Human Serv Procede de prevention d'infections a partir d'agents de terrorisme biologique avec des oligonucleotides cpg immunostimulateurs
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CN101517082B (zh) * 2006-09-27 2014-01-22 科勒制药有限责任公司 具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
PT2170353E (pt) * 2007-05-18 2015-09-16 Adiutide Pharmaceuticals Gmbh Análogos de oligonucleotídeo modificados por fosfato com atividade imunoestimulante
US8101371B2 (en) 2007-10-18 2012-01-24 Musc Foundation For Research Development Methods for the diagnosis of genitourinary cancer
JP5589274B2 (ja) * 2007-10-25 2014-09-17 東レ株式会社 免疫誘導剤
JP5359883B2 (ja) * 2007-11-28 2013-12-04 東レ株式会社 肝炎の治療剤又は予防剤
CN101559224B (zh) * 2008-04-18 2012-07-11 北京生物制品研究所 脊髓灰质炎疫苗
EP2471926A3 (fr) * 2010-12-30 2012-07-11 Intervet International BV Oligodésoxynucléotides immunostimulateurs
KR20140041505A (ko) * 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
CA2834440A1 (fr) * 2011-05-26 2012-11-29 Intervet International B.V. Oligodesoxynucleotides immunostimulatoires
BR112015027291A8 (pt) 2013-05-03 2019-12-24 Selecta Biosciences Inc uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor
EP2996719B1 (fr) * 2013-05-14 2019-06-26 Zoetis Services LLC Nouvelles compositions de vaccin comprenant des oligonucléotides immunostimulateurs
WO2016037164A1 (fr) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Procédés et compositions pour atténuer des réponses immunitaires contre des vecteurs de transfert viraux modulant l'expression génique
AR103428A1 (es) * 2015-01-16 2017-05-10 Hope City Anticuerpos de penetración celular
EP3490598A1 (fr) * 2016-07-26 2019-06-05 Bayer Animal Health GmbH Augmentation de la fertilité chez les espèces bovines
KR102753928B1 (ko) 2017-03-11 2025-01-14 셀렉타 바이오사이언시즈, 인크. 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
EP3980784A1 (fr) 2019-06-04 2022-04-13 Selecta Biosciences, Inc. Formulations et doses d'uricase pégylée
CN113440609A (zh) * 2020-03-27 2021-09-28 北京市农林科学院 一种双链rna复合物autp及其在疫苗制备中的应用
CN113493790A (zh) * 2020-04-01 2021-10-12 南京华普生物技术股份有限公司 具有免疫调节功能的CpG ODN及其应用
CN117925840A (zh) * 2024-01-30 2024-04-26 中国医学科学院基础医学研究所 Slfn11在cgt-odn治疗癌症疗效预测中的应用
CN117947031B (zh) * 2024-01-30 2024-12-24 中国医学科学院基础医学研究所 Cgt-odn在免疫调节中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022972A2 (fr) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Acides nucleiques immunostimulateurs
WO2004016805A2 (fr) * 2002-08-19 2004-02-26 Coley Pharmaceutical Group, Inc. Acides nucléiques immunostimulants
WO2004039829A2 (fr) * 2002-10-29 2004-05-13 Coley Pharmaceutical Group, Ltd. Techniques et produits relatifs au traitement et a la prevention de l'infection par le virus de l'hepatite c
WO2004087203A2 (fr) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Formulations de type huile-dans-l'eau a base d'acides nucleiques immunostimulateurs, et procedes d'utilisation associes
WO2004094671A2 (fr) * 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Procedes et produits pour identifier et evaluer des ligands des tlr

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
WO1998055495A2 (fr) * 1997-06-06 1998-12-10 Dynavax Technologies Corporation Oligonucleotides immunostimulateurs, compositions correspondantes et leurs procedes d'utilisation
WO1999058118A2 (fr) * 1998-05-14 1999-11-18 Cpg Immunopharmaceuticals Gmbh PROCEDES DE REGULATION DE L'HEMATOPOIESE AU MOYEN D'OLIGONUCLEOTIDES A CpG
DK1733735T3 (en) * 1998-05-22 2017-06-19 Ottawa Hospital Res Inst Methods and products for the induction of mucosal immunity
AU4992900A (en) * 1999-05-06 2000-11-21 Immune Response Corporation, The Hiv immunogenic compositions and methods
NZ517928A (en) * 1999-09-27 2004-09-24 Coley Pharm Gmbh Methods related to immunostimulatory nucleic acid-induced interferon
WO2001077377A2 (fr) * 2000-04-06 2001-10-18 Epigenomics Ag Diagnostic de maladies associees a la replication de l'adn
AU2001276371A1 (en) * 2000-06-30 2002-01-14 Epigenomics Ag Method and nucleic acids for analysing the methylation of genes implicated pharmacogenomics
DK1423528T3 (da) * 2000-09-01 2008-05-13 Epigenomics Ag Fremgangsmåde til bestemmelse af methyleringsgraden af bestemte cytosiner i genomisk DNA i sekvenskonteksten 5-CPG-3
ES2314099T3 (es) * 2001-08-17 2009-03-16 Coley Pharmaceutical Gmbh Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001022972A2 (fr) * 1999-09-25 2001-04-05 University Of Iowa Research Foundation Acides nucleiques immunostimulateurs
WO2004016805A2 (fr) * 2002-08-19 2004-02-26 Coley Pharmaceutical Group, Inc. Acides nucléiques immunostimulants
WO2004039829A2 (fr) * 2002-10-29 2004-05-13 Coley Pharmaceutical Group, Ltd. Techniques et produits relatifs au traitement et a la prevention de l'infection par le virus de l'hepatite c
WO2004087203A2 (fr) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Formulations de type huile-dans-l'eau a base d'acides nucleiques immunostimulateurs, et procedes d'utilisation associes
WO2004094671A2 (fr) * 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Procedes et produits pour identifier et evaluer des ligands des tlr

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004005476A2 *

Also Published As

Publication number Publication date
CN1678188A (zh) 2005-10-05
JP2005532067A (ja) 2005-10-27
EP1551221A2 (fr) 2005-07-13
WO2004005476A2 (fr) 2004-01-15
CA2494508A1 (fr) 2004-01-15
AU2003247880B2 (en) 2010-09-02
JP2009132737A (ja) 2009-06-18
AU2003247880A1 (en) 2004-01-23
CN1678188B (zh) 2012-10-10
SG167667A1 (en) 2011-01-28
WO2004005476A3 (fr) 2004-05-21

Similar Documents

Publication Publication Date Title
IL174848A0 (en) Nucleic acid constructs
TWI345971B (en) Nutritional compositions
IL164664A0 (en) Oligonucleotide compositions and their use for themodulation of immune responses
PT2290078T (pt) Ácidos nucleicos imunoestimuladores
IL208316A (en) Compound comprising nucleic acid strands
AU2003270310A8 (en) Compositions and methods for synthesizing nucleic acids
GB0319874D0 (en) Novel formulation
EP1556023A4 (fr) Compositions nutritionnelles ou therapeutiques
GB0317044D0 (en) Nucleic acid isolation
GB2417488B (en) Erucamide-free slip compositions
GB0210766D0 (en) Isolating nucleic acid
EP1644081A4 (fr) Connecteur de defibrillation a configurations multiples
GB0502687D0 (en) Rheometer
AU2003284127A8 (en) Nucleic acid supported protein complementation
GB0606187D0 (en) Acid containing oxaliplatin formulations
AU2003232036A8 (en) Nanoarchaeum nucleic acid molecule
GB0209382D0 (en) Isolating nucleic acid
HK1077474A (en) Nucleic acid compositions for stimulating immune responses
SG122904A1 (en) Nucleic acid preparation
GB2401551B (en) Stimulation aid
GB0314605D0 (en) Nucleic acid preparation
GB0202462D0 (en) Nucleic acid analysis
AU2003222173A1 (en) Nucleic acid compositions and methods for use
EP1696034A4 (fr) Methode de transfert d'acide nucleique
GB0226717D0 (en) DNA vaccination

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050203

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1077474

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20070704

17Q First examination report despatched

Effective date: 20071010

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1077474

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140201